Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib before and after surgery for BRAF V600-mutant melanoma
ISRCTN14595136Phase 2Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Feb 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and binimetinib in melanoma, sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Pathological complete response. Started Feb 2023; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on ISRCTN14595136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14595136.